SCHEMBL5674346

SCHEMBL5674346

O=C1Nc2ccc(Cl)c(Cl)c2C1c1ccccc1F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.41
MAPT P10636 1/20 0.41
PBRM1 Q86U86 2/20 0.40
ALDH1A1 P00352 2/20 0.40
HTR2C P28335 3/20 0.39
HTR1A P08908 2/20 0.38
HTR1D P28221 2/20 0.38
HTR7 P34969 2/20 0.38
HTR5A P47898 2/20 0.38
HRH1 P35367 1/20 0.38
LMNA P02545 1/20 0.38
IDO1 P14902 2/20 0.37
CDK1 P06493 1/20 0.37
CDK2 P24941 1/20 0.37
CSNK1D P48730 1/20 0.37
GSK3A P49840 1/20 0.37
GSK3B P49841 1/20 0.37
CDK5 Q00535 1/20 0.37
PBK Q96KB5 1/20 0.37
GAA P10253 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4590172 0.87 HTR2C (0.41) TP53MAPTALDH1A1HTR2CHTR1A
SCHEMBL7463894 0.79 HTR2C (0.42) TP53MAPTPBRM1ALDH1A1HTR2C
SCHEMBL5675400 0.77 PBRM1 (0.42) PBRM1LMNAIDO1GAATNKS2
SCHEMBL4590461 0.75 CACNB4 (0.47) TP53MAPTPBRM1LMNAIDO1
SCHEMBL7470476 0.72 GSK3B (0.42) TP53MAPTALDH1A1GSK3BCACNB4
SCHEMBL193482 0.69 MAPT (0.43) TP53MAPTALDH1A1LMNA
SCHEMBL4590075 0.69 HTR1A (0.48) TP53MAPTALDH1A1HTR2CHTR1A
SCHEMBL5530104 0.68 MEN1 (0.46) MAPTPBRM1ALDH1A1HTR2CLMNA
SCHEMBL7471103 0.67 MAPT (0.41) TP53MAPTALDH1A1HTR2CHTR7
SCHEMBL1408874 0.66 IDO1 (0.36) MAPTALDH1A1IDO1CDK1CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7119086-B2 Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use SANOFI-AVENTIS (FR) 2006-10-10 US disclosed
EP-1419150-B1 PHENYLSULFONYL-1,3-DIHYDRO-2H-INDOLE-2-ONE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE SANOFI AVENTIS (FR) 2005-04-27 EP disclosed
US-20040180878-A1 Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use SANOFI-AVENTIS (FR) 2004-09-16 US disclosed
EP-1419150-A2 PHENYLSULFONYL-1,3-DIHYDRO-2H-INDOLE-2-ONE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE Sanofi-Aventis (FR) 2004-05-19 EP disclosed
EP-1377565-A1 TETRAHYDROPYRAN DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS MERCK SHARP & DOHME LTD. (GB) 2004-01-07 EP disclosed
WO-2003008407-A2 PHENYLSULFONYL-1,3-DIHYDRO-2H-INDOLE-2-ONE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE SANOFI-SYNTHELABO (FR) 2003-01-30 WO disclosed
WO-2002057250-A1 TETRAHYDROPYRAN DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS MERCK SHARP & DOHME LIMITED (GB) 2002-07-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180878-A1 Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use AVPR2, AVPR1A, AVPR1B TP53 973/4885MAPT 3026/4885PBRM1 2588/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.